{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:37:46Z","timestamp":1740137866554,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600196"],"award-info":[{"award-number":["81600196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12967-018-1720-3","type":"journal-article","created":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T08:52:22Z","timestamp":1544431942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world use of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers\/\u03b2-blocks in Chinese patients before acute myocardial infarction occurs: patient characteristics and hospital follow-up"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-6674","authenticated-orcid":false,"given":"Xuhe","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,10]]},"reference":[{"key":"1720_CR1","first-page":"521","volume":"32","author":"C Weiwei","year":"2017","unstructured":"Weiwei C, Runlin G, Lisheng L, et al. Outline of Chinese cardiovascular disease report 2016. Chin J Circ. 2017;32:521\u20139.","journal-title":"Chin J Circ"},{"key":"1720_CR2","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"HJ Dargie","year":"2001","unstructured":"Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385\u201390.","journal-title":"Lancet"},{"key":"1720_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0140-6736(81)91101-6","volume":"2","author":"A Hjalmarson","year":"1981","unstructured":"Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet. 1981;2:823\u20137.","journal-title":"Lancet"},{"key":"1720_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","volume":"333","author":"L Kober","year":"1995","unstructured":"Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670\u20136.","journal-title":"N Engl J Med"},{"key":"1720_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","volume":"127","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American college of cardiology foundation\/American heart association task force on practice guidelines. Circulation. 2013;127:529\u201355.","journal-title":"Circulation"},{"key":"1720_CR6","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American college of cardiology\/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64:e139\u2013228.","journal-title":"J Am Coll Cardiol"},{"key":"1720_CR7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","volume":"355","author":"MD Flather","year":"2000","unstructured":"Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor myocardial infarction collaborative group. Lancet. 2000;355:1575\u201381.","journal-title":"Lancet"},{"key":"1720_CR8","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.jacc.2003.09.071","volume":"43","author":"SJ Kernis","year":"2004","unstructured":"Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol. 2004;43:1773\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1720_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10557-008-6097-8","volume":"22","author":"JC Kaski","year":"2008","unstructured":"Kaski JC, Fernandez-Berges D. Secondary prevention after acute myocardial infarction and coronary revascularisation: focus on angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther. 2008;22:185\u201391.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1720_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1161\/01.CIR.0000019582.39797.EF","volume":"106","author":"M Gheorghiade","year":"2002","unstructured":"Gheorghiade M, Goldstein S. Beta-blockers in the post-myocardial infarction patient. Circulation. 2002;106:394\u20138.","journal-title":"Circulation"},{"key":"1720_CR11","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635\u2013701.","journal-title":"Eur Heart J"},{"key":"1720_CR12","doi-asserted-by":"crossref","unstructured":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE inhibitor myocardial infarction collaborative group. Circulation. 1998;97:2202\u201312.","DOI":"10.1161\/01.CIR.97.22.2202"},{"key":"1720_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/2047487312449591","volume":"20","author":"K Kotseva","year":"2013","unstructured":"Kotseva K, Wood D, De Backer G, De Bacquer D. Use and effects of cardiac rehabilitation in patients with coronary heart disease: results from the EUROASPIRE III survey. Eur J Prev Cardiol. 2013;20:817\u201326.","journal-title":"Eur J Prev Cardiol"},{"key":"1720_CR14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/HJR.0b013e328338e5da","volume":"17","author":"T Bauer","year":"2010","unstructured":"Bauer T, Gitt AK, Junger C, et al. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. Eur J Cardiovasc Prev Rehabilit. 2010;17:576\u201381.","journal-title":"Eur J Cardiovasc Prev Rehabilit"},{"key":"1720_CR15","doi-asserted-by":"publisher","first-page":"e2971","DOI":"10.1097\/MD.0000000000002971","volume":"95","author":"PH Lee","year":"2016","unstructured":"Lee PH, Park GM, Kim YH, et al. Effect of Beta blockers and renin-angiotensin system inhibitors on survival in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Medicine. 2016;95:e2971.","journal-title":"Medicine"},{"key":"1720_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001343","author":"J Liu","year":"2015","unstructured":"Liu J, Masoudi FA, Spertus JA, et al. Patterns of use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers among patients with acute myocardial infarction in China from 2001 to 2011: China PEACE-retrospective AMI study. J Am Heart Assoc. 2015.\u00a0\n                    https:\/\/doi.org\/10.1161\/JAHA.114.001343\n                    \n                  .","journal-title":"J Am Heart Assoc"},{"key":"1720_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.amjcard.2014.12.008","volume":"115","author":"T Dohi","year":"2015","unstructured":"Dohi T, Maehara A, Brener SJ, et al. Utility of peak creatine kinase-MB measurements in predicting myocardial infarct size, left ventricular dysfunction, and outcome after first anterior wall acute myocardial infarction (from the INFUSE-AMI trial). Am J Cardiol. 2015;115:563\u201370.","journal-title":"Am J Cardiol"},{"key":"1720_CR18","first-page":"349","volume":"2","author":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","year":"1988","unstructured":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349\u201360.","journal-title":"Lancet."},{"key":"1720_CR19","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa0908610","volume":"362","author":"RW Yeh","year":"2010","unstructured":"Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155\u201365.","journal-title":"N Engl J Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1720-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-018-1720-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1720-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T19:12:50Z","timestamp":1575918770000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-018-1720-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1720"],"URL":"https:\/\/doi.org\/10.1186\/s12967-018-1720-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"15 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"346"}}